Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis

There is increasing prevalence of hypercholesterolemia among patients with osteoarthritis (OA) and rheumatoid arthritis (RA). We examined the effectiveness of statins on total cholesterol (TC), cardiovascular (CV) morbidity, and mortality in patients with OA or RA. A population-based cohort study wa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of rheumatology Ročník 39; číslo 1; s. 32
Hlavní autoři: Sheng, Xia, Murphy, Michael J, Macdonald, Thomas M, Wei, Li
Médium: Journal Article
Jazyk:angličtina
Vydáno: Canada 01.01.2012
Témata:
Aged
Aged, 80 and over
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - complications
Arthritis, Rheumatoid - mortality
Cardiovascular Diseases - blood
Cardiovascular Diseases - etiology
Cardiovascular Diseases - mortality
Cholesterol - blood
Cohort Studies
Databases, Factual
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypercholesterolemia - blood
Hypercholesterolemia - drug therapy
Hypercholesterolemia - etiology
Male
Middle Aged
Osteoarthritis - blood
Osteoarthritis - complications
Osteoarthritis - mortality
ISSN:1499-2752, 1499-2752
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract There is increasing prevalence of hypercholesterolemia among patients with osteoarthritis (OA) and rheumatoid arthritis (RA). We examined the effectiveness of statins on total cholesterol (TC), cardiovascular (CV) morbidity, and mortality in patients with OA or RA. A population-based cohort study was done using a record-linkage database in Tayside, Scotland. In total, 2024 OA or RA patients who had at least 2 separate TC measurements between 1993 and 2007 were studied. They were categorized into statin-exposed and statin-unexposed groups according to statin use status during followup. The main outcomes were TC concentration change from baseline, CV events, and all-cause mortality during the followup. Multivariate Cox regression models with a time-dependent variable for statins were employed to assess the risk of outcomes. Statin-associated TC concentrations in OA decreased by 15% in patients without CV disease (primary prevention, n = 1269) and 7% in patients with CV disease (secondary prevention, n = 247) from baseline of 5.30 mmol/l and 4.54 mmol/l, respectively. Correspondingly, in RA TC was reduced by 16% (n = 430) and 15% (n = 78) with baselines of 5.54 mmol/l and 4.95 mmol/l. In primary prevention, statins were associated with reduced CV events and all-cause mortality in RA patients [adjusted HR 0.45 (95% CI 0.20-0.98) and 0.43 (95% CI 0.20-0.92), respectively] and all-cause mortality in OA patients [adjusted HR 0.43 (95% CI 0.25-0.72)]. Statins were not associated with reduced risk of CV events or all-cause mortality in the secondary prevention of RA or OA patients [adjusted HR 0.68 (95% CI 0.30-1.54) and 0.52 (95% CI 0.20-1.34) for OA patients, and HR 0.58 (95% CI 0.07-4.79) and 0.79 (95% CI 0.18-3.53) for RA patients]. Statins reduced TC concentrations between 7% and 16% in patients with OA or RA. Statins were associated with reduced CV events and mortality in RA and mortality in OA in primary prevention.
AbstractList There is increasing prevalence of hypercholesterolemia among patients with osteoarthritis (OA) and rheumatoid arthritis (RA). We examined the effectiveness of statins on total cholesterol (TC), cardiovascular (CV) morbidity, and mortality in patients with OA or RA.OBJECTIVEThere is increasing prevalence of hypercholesterolemia among patients with osteoarthritis (OA) and rheumatoid arthritis (RA). We examined the effectiveness of statins on total cholesterol (TC), cardiovascular (CV) morbidity, and mortality in patients with OA or RA.A population-based cohort study was done using a record-linkage database in Tayside, Scotland. In total, 2024 OA or RA patients who had at least 2 separate TC measurements between 1993 and 2007 were studied. They were categorized into statin-exposed and statin-unexposed groups according to statin use status during followup. The main outcomes were TC concentration change from baseline, CV events, and all-cause mortality during the followup. Multivariate Cox regression models with a time-dependent variable for statins were employed to assess the risk of outcomes.METHODSA population-based cohort study was done using a record-linkage database in Tayside, Scotland. In total, 2024 OA or RA patients who had at least 2 separate TC measurements between 1993 and 2007 were studied. They were categorized into statin-exposed and statin-unexposed groups according to statin use status during followup. The main outcomes were TC concentration change from baseline, CV events, and all-cause mortality during the followup. Multivariate Cox regression models with a time-dependent variable for statins were employed to assess the risk of outcomes.Statin-associated TC concentrations in OA decreased by 15% in patients without CV disease (primary prevention, n = 1269) and 7% in patients with CV disease (secondary prevention, n = 247) from baseline of 5.30 mmol/l and 4.54 mmol/l, respectively. Correspondingly, in RA TC was reduced by 16% (n = 430) and 15% (n = 78) with baselines of 5.54 mmol/l and 4.95 mmol/l. In primary prevention, statins were associated with reduced CV events and all-cause mortality in RA patients [adjusted HR 0.45 (95% CI 0.20-0.98) and 0.43 (95% CI 0.20-0.92), respectively] and all-cause mortality in OA patients [adjusted HR 0.43 (95% CI 0.25-0.72)]. Statins were not associated with reduced risk of CV events or all-cause mortality in the secondary prevention of RA or OA patients [adjusted HR 0.68 (95% CI 0.30-1.54) and 0.52 (95% CI 0.20-1.34) for OA patients, and HR 0.58 (95% CI 0.07-4.79) and 0.79 (95% CI 0.18-3.53) for RA patients].RESULTSStatin-associated TC concentrations in OA decreased by 15% in patients without CV disease (primary prevention, n = 1269) and 7% in patients with CV disease (secondary prevention, n = 247) from baseline of 5.30 mmol/l and 4.54 mmol/l, respectively. Correspondingly, in RA TC was reduced by 16% (n = 430) and 15% (n = 78) with baselines of 5.54 mmol/l and 4.95 mmol/l. In primary prevention, statins were associated with reduced CV events and all-cause mortality in RA patients [adjusted HR 0.45 (95% CI 0.20-0.98) and 0.43 (95% CI 0.20-0.92), respectively] and all-cause mortality in OA patients [adjusted HR 0.43 (95% CI 0.25-0.72)]. Statins were not associated with reduced risk of CV events or all-cause mortality in the secondary prevention of RA or OA patients [adjusted HR 0.68 (95% CI 0.30-1.54) and 0.52 (95% CI 0.20-1.34) for OA patients, and HR 0.58 (95% CI 0.07-4.79) and 0.79 (95% CI 0.18-3.53) for RA patients].Statins reduced TC concentrations between 7% and 16% in patients with OA or RA. Statins were associated with reduced CV events and mortality in RA and mortality in OA in primary prevention.CONCLUSIONStatins reduced TC concentrations between 7% and 16% in patients with OA or RA. Statins were associated with reduced CV events and mortality in RA and mortality in OA in primary prevention.
There is increasing prevalence of hypercholesterolemia among patients with osteoarthritis (OA) and rheumatoid arthritis (RA). We examined the effectiveness of statins on total cholesterol (TC), cardiovascular (CV) morbidity, and mortality in patients with OA or RA. A population-based cohort study was done using a record-linkage database in Tayside, Scotland. In total, 2024 OA or RA patients who had at least 2 separate TC measurements between 1993 and 2007 were studied. They were categorized into statin-exposed and statin-unexposed groups according to statin use status during followup. The main outcomes were TC concentration change from baseline, CV events, and all-cause mortality during the followup. Multivariate Cox regression models with a time-dependent variable for statins were employed to assess the risk of outcomes. Statin-associated TC concentrations in OA decreased by 15% in patients without CV disease (primary prevention, n = 1269) and 7% in patients with CV disease (secondary prevention, n = 247) from baseline of 5.30 mmol/l and 4.54 mmol/l, respectively. Correspondingly, in RA TC was reduced by 16% (n = 430) and 15% (n = 78) with baselines of 5.54 mmol/l and 4.95 mmol/l. In primary prevention, statins were associated with reduced CV events and all-cause mortality in RA patients [adjusted HR 0.45 (95% CI 0.20-0.98) and 0.43 (95% CI 0.20-0.92), respectively] and all-cause mortality in OA patients [adjusted HR 0.43 (95% CI 0.25-0.72)]. Statins were not associated with reduced risk of CV events or all-cause mortality in the secondary prevention of RA or OA patients [adjusted HR 0.68 (95% CI 0.30-1.54) and 0.52 (95% CI 0.20-1.34) for OA patients, and HR 0.58 (95% CI 0.07-4.79) and 0.79 (95% CI 0.18-3.53) for RA patients]. Statins reduced TC concentrations between 7% and 16% in patients with OA or RA. Statins were associated with reduced CV events and mortality in RA and mortality in OA in primary prevention.
Author Murphy, Michael J
Sheng, Xia
Macdonald, Thomas M
Wei, Li
Author_xml – sequence: 1
  givenname: Xia
  surname: Sheng
  fullname: Sheng, Xia
  organization: Medicines Monitoring Unit, Division of Medical Sciences, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland
– sequence: 2
  givenname: Michael J
  surname: Murphy
  fullname: Murphy, Michael J
– sequence: 3
  givenname: Thomas M
  surname: Macdonald
  fullname: Macdonald, Thomas M
– sequence: 4
  givenname: Li
  surname: Wei
  fullname: Wei, Li
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22045835$$D View this record in MEDLINE/PubMed
BookMark eNpNUMtOwzAQtBCIPuDIFfnGKcV2nMQ-oqo8pEpc4Bw5fqiuHLvYTqV-Az9NKK3EaWc1M6vZmYFLH7wG4A6jRck4f9zGjR76BcaoxOwCTDHlvCBNRS7_4QmYpbRFCNe0ZtdgQgiiFSurKfheGaNltnvtdUowGJiyyNaP0MMcsnBQboLTKesYHBReQSmismEvkhyciFDZpEXSR0o4V0gxjFsf4ui1-QCth2F0BxHzJtps01F5TC1ysKPpTNyAKyNc0renOQefz6uP5Wuxfn95Wz6tC0lJkwtVIkVZ1YiGMIpETZhsaK2YaUzFeVcp1fDKdIpTRHAnFWYMGc1ZaYhpuo6SOXj4u7uL4WsYX2t7m6R2TngdhtRyXNKS_fY2B_cn5dD1WrW7aHsRD-25P_IDsNl4dQ
CitedBy_id crossref_primary_10_1177_1759720X16664306
crossref_primary_10_1093_rheumatology_kew039
crossref_primary_10_1016_j_phrs_2014_02_003
crossref_primary_10_1016_j_rehab_2016_01_006
crossref_primary_10_3389_fmed_2023_1297482
crossref_primary_10_1111_1756_185X_12415
crossref_primary_10_1097_BOR_0b013e3283604218
crossref_primary_10_3390_diagnostics14232725
crossref_primary_10_1016_j_rcreue_2018_10_004
crossref_primary_10_1002_acr_22029
crossref_primary_10_1016_j_rdc_2013_10_005
crossref_primary_10_7453_gahmj_2012_1_2_009
crossref_primary_10_3390_jcdd12090367
crossref_primary_10_1093_ehjcvp_pvz033
crossref_primary_10_2174_1381612825666190430113212
crossref_primary_10_3109_08916934_2015_1118761
crossref_primary_10_1016_j_ijcard_2015_01_069
crossref_primary_10_1007_s10522_024_10112_y
crossref_primary_10_1097_MD_0000000000042230
crossref_primary_10_1016_j_jbspin_2014_01_009
crossref_primary_10_1155_2012_147354
crossref_primary_10_1146_annurev_med_060911_090007
crossref_primary_10_3389_fcvm_2022_894577
crossref_primary_10_1136_annrheumdis_2012_202789
crossref_primary_10_1136_annrheumdis_2017_211074
crossref_primary_10_3390_biomedicines13040870
crossref_primary_10_1016_j_imlet_2015_12_009
crossref_primary_10_1007_s12016_018_8714_z
crossref_primary_10_3389_fphar_2021_726044
crossref_primary_10_1093_rheumatology_kew497
crossref_primary_10_1186_s12981_016_0105_z
crossref_primary_10_1016_j_semarthrit_2020_11_010
crossref_primary_10_1007_s00393_011_0923_2
crossref_primary_10_1136_annrheumdis_2018_214075
crossref_primary_10_1177_1759720X13491025
crossref_primary_10_1007_s11926_012_0271_5
crossref_primary_10_1155_2014_367359
crossref_primary_10_1002_acr_24866
crossref_primary_10_63845_589kvm75
crossref_primary_10_1016_j_cgh_2022_06_011
crossref_primary_10_1016_j_ijcard_2017_11_009
crossref_primary_10_2217_ijr_14_40
crossref_primary_10_3109_03009742_2015_1028997
crossref_primary_10_3389_fmed_2018_00024
crossref_primary_10_1002_acr_23609
crossref_primary_10_1136_annrheumdis_2015_207714
crossref_primary_10_1016_j_therap_2019_01_004
crossref_primary_10_1097_RHU_0b013e31827846b1
crossref_primary_10_1016_j_autrev_2015_06_004
crossref_primary_10_1002_art_34524
crossref_primary_10_1016_j_phrs_2020_105057
crossref_primary_10_3390_ijms150711324
crossref_primary_10_1016_j_biopha_2017_06_053
crossref_primary_10_1016_j_rhum_2013_12_017
crossref_primary_10_1097_BOR_0b013e32835fd7f8
crossref_primary_10_1007_s00011_013_0702_4
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.3899/jrheum.110318
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1499-2752
ExternalDocumentID 22045835
Genre Journal Article
GrantInformation_xml – fundername: Medical Research Council
  grantid: G106/1249
GroupedDBID ---
.55
.GJ
0R~
123
18M
1KJ
3O-
4.4
53G
5RE
6PF
AAFWJ
AAQQT
AAWTL
ABCQX
ABJNI
ACGFO
ACGFS
ADCBC
AENEX
AFFNX
AI.
ALMA_UNASSIGNED_HOLDINGS
BR6
CGR
CUY
CVF
EBS
ECM
EIF
EJD
EMOBN
F5P
H13
HZ~
J5H
L7B
MJL
NPM
O9-
P0W
P2P
RHI
SJN
TJE
VH1
W2D
X7M
XBR
XDU
XOL
YQJ
ZGI
ZXE
ZXP
7X8
ID FETCH-LOGICAL-c427t-d30d4857a72840a628c746d8f7f599b5dd795fbd94021bcd1880fe983f2f7bb42
IEDL.DBID 7X8
ISICitedReferencesCount 65
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000299400500008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1499-2752
IngestDate Thu Jul 10 23:26:36 EDT 2025
Mon Jul 21 06:03:18 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c427t-d30d4857a72840a628c746d8f7f599b5dd795fbd94021bcd1880fe983f2f7bb42
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.jrheum.org/content/jrheum/39/1/32.full.pdf
PMID 22045835
PQID 913438275
PQPubID 23479
ParticipantIDs proquest_miscellaneous_913438275
pubmed_primary_22045835
PublicationCentury 2000
PublicationDate 2012-01-01
PublicationDateYYYYMMDD 2012-01-01
PublicationDate_xml – month: 01
  year: 2012
  text: 2012-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Canada
PublicationPlace_xml – name: Canada
PublicationTitle Journal of rheumatology
PublicationTitleAlternate J Rheumatol
PublicationYear 2012
SSID ssj0016468
Score 2.3137002
Snippet There is increasing prevalence of hypercholesterolemia among patients with osteoarthritis (OA) and rheumatoid arthritis (RA). We examined the effectiveness of...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 32
SubjectTerms Aged
Aged, 80 and over
Arthritis, Rheumatoid - blood
Arthritis, Rheumatoid - complications
Arthritis, Rheumatoid - mortality
Cardiovascular Diseases - blood
Cardiovascular Diseases - etiology
Cardiovascular Diseases - mortality
Cholesterol - blood
Cohort Studies
Databases, Factual
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypercholesterolemia - blood
Hypercholesterolemia - drug therapy
Hypercholesterolemia - etiology
Male
Middle Aged
Osteoarthritis - blood
Osteoarthritis - complications
Osteoarthritis - mortality
Title Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis
URI https://www.ncbi.nlm.nih.gov/pubmed/22045835
https://www.proquest.com/docview/913438275
Volume 39
WOSCitedRecordID wos000299400500008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwELWAIsSFfSmbfOBqtfES2yeEEBUHWvUAqLcojmO1qE1KF36Cn2bspCAOiAOXKJFjKbYn42e_mWeErnOmbCyMJT6rkfBIOZIaCo_axFoyTqMgu_jyKHs9NRjofh2bM6_DKlc-MThqW2Z-j7zlGWKmqBQ30zfiD43y5Gp9gsY6ajBAMt6o5eCbRIh5lQkHoJ5ARVpJbHpBudbrbJgvJz4GnkXqd3AZJpnO7j8_bw_t1OgS31bmsI_W8uIAbXVr_vwQfVRixbWHw6XDPqFoVMBtgRclAHHs3WFQTyjHOC0szn4ErOKa0AlF6XhMsnQJT5MA4gHQ41GBfdpICRY5DHpJ4c3QD7C8H0GlVcEReu7cP909kPo4BpJxKhfEsrblSshUwpTWTmOqMsljq5x0QmsjrJVaOGM1LEkjk1mv9OZyrZijThrD6THaKMoiP0XYwLqYtqHFLI65gxEB15Br5_GbFM7xJsKrXk7A3D2HkRZ5uZwnX_3cRCfVSCXTSpYjoTSQwOLs78rnaBuAD622Ui5Qw8Gvnl-izewdmj-7CmYE116_-wk4hdXh
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effectiveness+of+statins+on+total+cholesterol+and+cardiovascular+disease+and+all-cause+mortality+in+osteoarthritis+and+rheumatoid+arthritis&rft.jtitle=Journal+of+rheumatology&rft.au=Sheng%2C+Xia&rft.au=Murphy%2C+Michael+J&rft.au=Macdonald%2C+Thomas+M&rft.au=Wei%2C+Li&rft.date=2012-01-01&rft.eissn=1499-2752&rft.volume=39&rft.issue=1&rft.spage=32&rft_id=info:doi/10.3899%2Fjrheum.110318&rft_id=info%3Apmid%2F22045835&rft_id=info%3Apmid%2F22045835&rft.externalDocID=22045835
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1499-2752&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1499-2752&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1499-2752&client=summon